Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT00578266

Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The objective of this trial is to make an initial assessment for this new treatment regimen and to show it is equal or superior to the current standard practice. With this initial assessment be hope to gain information suggesting further study of this regimen or discontinuation of this regimen before exposing large numbers of patients to this new treatment option. We also will gain experience with this new regimen giving insights as to possible modifications in dosing and monitoring and selection of patients for future treatment in case of positive results. For this initial study we plan to enroll up to 24 patients.

Status: 
Recruiting
Study Date: 
Tue, 02/02/2010 to Wed, 02/01/2017
Bone Marrow Disease(s): 
aplastic anemia
Intervention: 
Drug: Cyclophosphamide,Campath IH and TBI DAY 5 TREATMENT 6 5 CYTOXAN 50 mg/kg WITH MESNA 5 CYTOXAN 50 mg/kg WITH MESNA; 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH; 2 TBI; CAMPATH; TACROLIMUS 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)